MedTrace Logo

Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors

NCT07146672 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-08-28

No results posted yet for this study

Summary

The study is a controlled, open-label exploratory clinical trial.

Conditions

  • Solid Tumor Cancer

Interventions

BIOLOGICAL

Super DC Vaccine

Super DC Cell Injection

Sponsors & Collaborators

  • Shanghai Cell Therapy Group Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07146672 on ClinicalTrials.gov